AU2016294858B2 - Radiolabelled antibody fragments for use in treating cancer - Google Patents

Radiolabelled antibody fragments for use in treating cancer Download PDF

Info

Publication number
AU2016294858B2
AU2016294858B2 AU2016294858A AU2016294858A AU2016294858B2 AU 2016294858 B2 AU2016294858 B2 AU 2016294858B2 AU 2016294858 A AU2016294858 A AU 2016294858A AU 2016294858 A AU2016294858 A AU 2016294858A AU 2016294858 B2 AU2016294858 B2 AU 2016294858B2
Authority
AU
Australia
Prior art keywords
vhh
radiolabelled
functional fragment
her2
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016294858A
Other languages
English (en)
Other versions
AU2016294858A1 (en
Inventor
Matthias D'HUYVETTER
Jens DE VOS
Nick Devoogdt
Tony Lahoutte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Brussel VUB
Original Assignee
Vrije Universiteit Brussel VUB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrije Universiteit Brussel VUB filed Critical Vrije Universiteit Brussel VUB
Publication of AU2016294858A1 publication Critical patent/AU2016294858A1/en
Application granted granted Critical
Publication of AU2016294858B2 publication Critical patent/AU2016294858B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
AU2016294858A 2015-07-17 2016-07-15 Radiolabelled antibody fragments for use in treating cancer Active AU2016294858B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562193700P 2015-07-17 2015-07-17
US62/193,700 2015-07-17
EP16153372 2016-01-29
EP16153372.4 2016-01-29
PCT/EP2016/066934 WO2017013026A1 (en) 2015-07-17 2016-07-15 Radiolabelled antibody fragments for use in treating cancer

Publications (2)

Publication Number Publication Date
AU2016294858A1 AU2016294858A1 (en) 2018-02-01
AU2016294858B2 true AU2016294858B2 (en) 2022-08-11

Family

ID=57833837

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016294858A Active AU2016294858B2 (en) 2015-07-17 2016-07-15 Radiolabelled antibody fragments for use in treating cancer

Country Status (9)

Country Link
US (2) US11298433B2 (OSRAM)
EP (1) EP3325020B1 (OSRAM)
JP (1) JP6917357B2 (OSRAM)
KR (2) KR20180042226A (OSRAM)
CN (1) CN108025093B (OSRAM)
AU (1) AU2016294858B2 (OSRAM)
CA (1) CA2991398A1 (OSRAM)
MX (1) MX390949B (OSRAM)
WO (1) WO2017013026A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018233624A1 (zh) * 2017-06-20 2018-12-27 和迈生物科技有限公司 抗Her2纳米抗体及其编码序列和用途
EP3967674A1 (en) * 2020-09-11 2022-03-16 Precirix N.V. Reactions of radioactive compounds facilitated by a solid phase
CN112561871B (zh) * 2020-12-08 2021-09-03 中国医学科学院北京协和医院 一种基于平扫ct图像的主动脉夹层分割方法和装置
CN117321081A (zh) * 2021-02-22 2023-12-29 雅博得乐医疗公司 用于靶向放射性同位素疗法的免疫缀合物
JP2025522306A (ja) * 2022-05-23 2025-07-15 セライアス・インコーポレイテッド Ｈｅｒ２－結合剤およびその使用
CA3265385A1 (en) 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DLL3 BINDING MOLECULES AND THEIR USES
CN116719074A (zh) * 2023-05-29 2023-09-08 中国核电工程有限公司 一种两栖生物辐射剂量率的获取方法及装置
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209343A1 (en) * 2009-02-17 2010-08-19 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0784684B8 (en) 1994-09-16 2008-03-26 Cancer Research Institute of Contra Costa RECOMBINANT PEPTIDES DERIVED FROM THE Mc3 ANTI-BA46 ANTIBODY, METHODS OF USE THEREOF, AND METHODS OF HUMANIZING ANTIBODY PEPTIDES
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69738166T2 (de) 1996-06-27 2008-06-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
AU3041100A (en) 1999-01-05 2000-07-24 Unilever Plc Binding of antibody fragments to solid supports
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
CN1252264C (zh) 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原－结合蛋白抑制病毒感染
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
WO2001040310A2 (en) 1999-11-29 2001-06-07 Unilever Plc Immobilisation of proteins using a polypeptide segment
EP1233987B1 (en) 1999-11-29 2009-08-19 Bac Ip B.V. Immobilized single domain antigen-binding molecules
DE60138333D1 (de) 2000-03-14 2009-05-28 Unilever Nv Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
DK1360207T3 (da) 2000-12-13 2011-09-05 Bac Ip B V Proteinarray af variable domæner af tunge immunoglobulinkæder fra kameler
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
WO2003054016A2 (en) 2001-12-21 2003-07-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
EP1558646A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
US9028816B2 (en) 2003-01-10 2015-05-12 Ablynx N.V. Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
US20090304590A1 (en) 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
EP2215125A1 (en) * 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20110200525A1 (en) 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US9670275B2 (en) 2012-01-23 2017-06-06 Ablynx N.V. Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2014140376A1 (en) 2013-03-15 2014-09-18 Vib Vzw Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
US10174117B2 (en) * 2013-06-11 2019-01-08 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
WO2015073746A2 (en) 2013-11-13 2015-05-21 Whitehead Institute For Biomedical Research 18f labeling of proteins using sortases
AU2015295687C1 (en) 2014-07-29 2019-10-17 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
WO2016016329A1 (en) * 2014-07-29 2016-02-04 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209343A1 (en) * 2009-02-17 2010-08-19 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D'HUYVETTER, M. et al., "Targeted Radionuclide Therapy with A 177 Lu-labeled Anti-HER2 Nanobody", Theranostics. 2014, Vol. 4, No. 7, pages 708 - 720 *

Also Published As

Publication number Publication date
CN108025093A (zh) 2018-05-11
KR20180042226A (ko) 2018-04-25
CA2991398A1 (en) 2017-01-26
US12440586B2 (en) 2025-10-14
KR20250174696A (ko) 2025-12-12
US20180200393A1 (en) 2018-07-19
US11298433B2 (en) 2022-04-12
MX2018000598A (es) 2018-05-11
US20220323620A1 (en) 2022-10-13
BR112018000672A2 (pt) 2018-09-18
WO2017013026A1 (en) 2017-01-26
JP2018532689A (ja) 2018-11-08
CN108025093B (zh) 2022-02-11
JP6917357B2 (ja) 2021-08-11
EP3325020A1 (en) 2018-05-30
AU2016294858A1 (en) 2018-02-01
MX390949B (es) 2025-03-21
EP3325020B1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
US12440586B2 (en) Radiolabelled antibody fragments for use in treating cancer
AU2015295687C1 (en) Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
US11660356B2 (en) Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
US20230340111A1 (en) Antibody fragment against folr1
US20230381350A1 (en) Antibody fragment against fap
HK1256178A1 (en) Radiolabelled antibody fragments for use in treating cancer
HK1256178B (en) Radiolabelled antibody fragments for use in treating cancer
BR112018000672B1 (pt) Kit e uso de um domínio variável de cadeia pesada marcado radioativamente derivado de um anticorpo de cadeia pesada (vhh) ou um fragmento funcional do mesmo no tratamento de câncer
HK40038884A (en) Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
HK1239512A1 (en) Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
HK1239512B (en) Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
BR112017001782B1 (pt) Domínio variável de cadeia pesada radiomarcado derivado de anticorpo de cadeia pesada (vhh), ou um fragmento funcional do mesmo, seu uso, e composição farmacêutica
IL165753A (en) HUMANIZED MONOCLONAL ANTIBODY hPAM4, A CONJUGATE COMPRISING IT AND AN ANTIBODY COMPRISING THE SAME OR FRAGMENTS THEREOF

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)